M.tuberculosis mutants lacking oxygenated mycolates show increased immunogenicity and protective efficacy as compared to M. bovis BCG vaccine in an experimental mouse model.
Hedhli, Dorsaf Denis, Olivier J. Barkan, Daniel Daffé, Mamadou Glickman, Michael S. Huygen, Kris
Hedhli, Dorsaf
Denis, Olivier J.
Barkan, Daniel
Daffé, Mamadou
Glickman, Michael S.
Huygen, Kris
Citations
Altmetric:
Abstract
The existing vaccine against tuberculosis (M. bovis BCG) exerts some protection against the extrapulmonary forms of the disease, particularly in young children, but is not very effective against the pulmonary form of TB, which often results from the reactivation of a latent M. tuberculosis (M.tb)infection. Among the new approaches in TB vaccine development, live attenuated M.tb mutants are a promising new avenue. Here we report on the vaccine potential of two highly attenuated M.tb mutants, MGM1991 and M.tbhma
Description
Date
2013-07-01
Journal Title
Journal ISSN
Volume Title
Publisher
Chapter title
Publication type
Peer reviewed scientific article
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Animals, Bacterial Load, BCG Vaccine, Disease Models, Animal, Enzyme-Linked Immunospot Assay, Injections, Subcutaneous, Interferon-gamma, Interleukin-17, Lymph Nodes, mice, Mice, Inbred C57BL, Mutation, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Organ Specificity, Oxygen, Species Specificity, Spleen, Th1 Cells, Th17 Cells, Trachea, Treatment Outcome, Tuberculosis, Vaccination, virulence